Protective α1-antitrypsin effects in autoimmune vasculitis are compromised by methionine oxidation.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 11 03 2022
accepted: 13 09 2022
pubmed: 21 9 2022
medline: 3 12 2022
entrez: 20 9 2022
Statut: epublish

Résumé

BackgroundAntineutrophil cytoplasmic autoantibody-associated (ANCA-associated) vasculitidies (AAV) are life-threatening systemic autoimmune conditions. ANCAs directed against proteinase 3 (PR3) or myeloperoxidase (MPO) bind their cell surface-presented antigen, activate neutrophils, and cause vasculitis. An imbalance between PR3 and its major inhibitor α1-antitrypsin (AAT) was proposed to underlie PR3- but not MPO-AAV. We measured AAT and PR3 in healthy individuals and patients with AAV and studied protective AAT effects pertaining to PR3- and MPO-ANCA.MethodsPlasma and blood neutrophils were assessed for PR3 and AAT. WT, mutant, and oxidation-resistant AAT species were produced to characterize AAT-PR3 interactions by flow cytometry, immunoblotting, fluorescence resonance energy transfer assays, and surface plasmon resonance measurements. Neutrophil activation was measured using the ferricytochrome C assay and AAT methionine-oxidation by Parallel Reaction Monitoring.ResultsWe found significantly increased PR3 and AAT pools in patients with both PR3- and MPO-AAV; however, only in PR3-AAV did the PR3 pool correlate with the ANCA titer, inflammatory response, and disease severity. Mechanistically, AAT prevented PR3 from binding to CD177, thereby reducing neutrophil surface antigen for ligation by PR3-ANCA. Active patients with PR3-AAV showed critical methionine-oxidation in plasma AAT that was recapitulated by ANCA-activated neutrophils. The protective PR3-related AAT effects were compromised by methionine-oxidation in the AAT reactive center loop but preserved when 2 critical methionines were substituted with valine and leucine.ConclusionPathogenic differences between PR3- and MPO-AAV are related to AAT regulation of membrane-PR3, attenuating neutrophil activation by PR3-ANCA rather than MPO-ANCA. Oxidation-resistant AAT could serve as adjunctive therapy in PR3-AAV.FUNDINGThis work was supported by KE 576/10-1 from the Deutsche Forschungsgemeinschaft, SCHR 771/8-1 from the Deutsche Forschungsgemeinschaft, grant 394046635 - SFB 1365 from the Deutsche Forschungsgemeinschaft, and ECRC grants.

Identifiants

pubmed: 36125911
pii: 160089
doi: 10.1172/JCI160089
pmc: PMC9711875
doi:
pii:

Substances chimiques

Antibodies, Antineutrophil Cytoplasmic 0
Methionine AE28F7PNPL
Myeloblastin EC 3.4.21.76
Peroxidase EC 1.11.1.7
alpha 1-Antitrypsin 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

J Leukoc Biol. 2016 Dec;100(6):1443-1452
pubmed: 27365530
J Am Soc Nephrol. 2012 Mar;23(3):470-82
pubmed: 22241891
Auris Nasus Larynx. 2001 Nov;28(4):311-4
pubmed: 11694374
J Heart Lung Transplant. 2018 Aug;37(8):1021-1028
pubmed: 29776812
J Leukoc Biol. 1999 Dec;66(6):989-95
pubmed: 10614782
Blood. 2007 May 15;109(10):4487-93
pubmed: 17244676
J Am Soc Nephrol. 2015 Oct;26(10):2314-27
pubmed: 25956510
Blood. 2004 Sep 1;104(5):1411-8
pubmed: 15150076
J Am Soc Nephrol. 2002 Sep;13(9):2232-8
pubmed: 12191967
Blood. 2007 Dec 1;110(12):4086-95
pubmed: 17712045
PLoS One. 2012;7(1):e28626
pubmed: 22247758
Ann Rheum Dis. 2013 Jun;72(6):1003-10
pubmed: 22962314
Proc Natl Acad Sci U S A. 1982 Mar;79(6):2041-5
pubmed: 6979049
Chest. 2020 Nov;158(5):1919-1922
pubmed: 32417149
Eur J Clin Invest. 1997 Aug;27(8):696-702
pubmed: 9279535
J Autoimmun. 2010 Dec;35(4):299-308
pubmed: 20810247
J Am Soc Nephrol. 2004 Aug;15(8):2103-14
pubmed: 15284296
Kidney Int. 2015 Oct;88(4):764-75
pubmed: 26061547
FEBS Lett. 1995 Oct 23;374(1):29-33
pubmed: 7589506
Proc Natl Acad Sci U S A. 2012 Sep 25;109(39):E2615-24
pubmed: 22955884
Nature. 2018 Jun;558(7708):73-79
pubmed: 29875488
J Clin Invest. 2015 Nov 2;125(11):4107-21
pubmed: 26436651
J Immunol. 2013 Sep 1;191(5):2700-7
pubmed: 23904161
Clin Exp Immunol. 2012 Sep;169(3):220-8
pubmed: 22861361
Nat Rev Dis Primers. 2020 Aug 27;6(1):71
pubmed: 32855422
J Immunol. 2010 Jul 1;185(1):387-99
pubmed: 20530264
Arthritis Rheumatol. 2018 Jul;70(7):1114-1121
pubmed: 29693324
N Engl J Med. 2012 Jul 19;367(3):214-23
pubmed: 22808956
J Leukoc Biol. 2013 Oct;94(4):711-21
pubmed: 23650620
J Biol Chem. 1978 Oct 25;253(20):7142-4
pubmed: 701239
Science. 1979 Dec 14;206(4424):1315-6
pubmed: 316188
J Am Soc Nephrol. 1999 Jun;10(6):1224-33
pubmed: 10361860
J Exp Med. 2017 Jul 3;214(7):2089-2101
pubmed: 28559244
J Biol Chem. 1979 May 25;254(10):4022-6
pubmed: 312289
J Am Soc Nephrol. 2006 Nov;17(11):3185-91
pubmed: 17005932
Ann Rheum Dis. 2009 Dec;68(12):1827-32
pubmed: 19054820
Thorax. 2012 Aug;67(8):669-74
pubmed: 22426792
Kidney Int. 1993 Mar;43(3):682-92
pubmed: 8455368
J Am Soc Nephrol. 2005 Jul;16(7):2216-24
pubmed: 15901769
JCI Insight. 2020 Aug 6;5(15):
pubmed: 32759494
Rheumatology (Oxford). 2019 Oct 1;58(10):1731-1739
pubmed: 30805643
Sci Rep. 2017 Feb 27;7:43328
pubmed: 28240246
Bioinformatics. 2010 Apr 1;26(7):966-8
pubmed: 20147306
Am J Pathol. 2009 Apr;174(4):1212-20
pubmed: 19264905
Arthritis Rheumatol. 2017 May;69(5):1054-1066
pubmed: 28029757
J Clin Apher. 1987;3(3):185-90
pubmed: 3558344
Arthritis Rheum. 2013 Jan;65(1):1-11
pubmed: 23045170
J Am Soc Nephrol. 2006 Dec;17(12):3355-64
pubmed: 17108314
J Clin Invest. 2002 Oct;110(7):955-63
pubmed: 12370273
J Clin Invest. 1999 Aug;104(3):337-44
pubmed: 10430615
Kidney Int. 2004 Jun;65(6):2172-83
pubmed: 15149330
Anal Chem. 2003 Feb 1;75(3):663-70
pubmed: 12585499
J Am Soc Nephrol. 2003 Jan;14(1):68-75
pubmed: 12506139
Ann Rheum Dis. 2011 Oct;70(10):1851-6
pubmed: 21821620
J Clin Invest. 2010 Sep;120(9):3209-19
pubmed: 20714105
J Biol Chem. 1980 May 10;255(9):3931-4
pubmed: 6989830

Auteurs

Maximilian Ebert (M)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Uwe Jerke (U)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Claudia Eulenberg-Gustavus (C)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.

Lovis Kling (L)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Germany.

Dieter Jenne (D)

Max-Planck-Institute of Neurobiology, Planegg-Martinsried, Germany.

Marieluise Kirchner (M)

Core Unit Proteomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Philipp Mertins (P)

Core Unit Proteomics, Berlin Institute of Health at Charité - Universitätsmedizin Berlin and Max Delbrück Center for Molecular Medicine, Berlin, Germany.

Markus Bieringer (M)

Department of Nephrology, Helios Klinikum Berlin-Buch, Berlin, Germany.

Saban Elitok (S)

Department of Nephrology and Endocrinology, Ernst von Bergmann Klinikum, Potsdam, Germany.

Kai-Uwe Eckardt (KU)

Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Germany.

Adrian Schreiber (A)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Germany.

Alan D Salama (AD)

University College London, Royal Free Hospital, London, United Kingdom.

Ralph Kettritz (R)

Experimental and Clinical Research Center, a cooperation between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité - Universitätsmedizin Berlin, Berlin, Germany.
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
Department of Nephrology and Medical Intensive Care, Charité - Universitätsmedizin Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH